Dew, Production costs notwithstanding. If ART-123 were ever proven superior to Atryn in our medical enviornment patients or even the "system" would pay the difference. I am still interested in trying to understand the role of protein C and if the anti inflamatory effects of each agent would be equivalent. By the way I continue to look for the unexpected curve ball in that Elan continues to be mentioned as a big pharma partner and the tysabri program while previously put in suspended animation, seems ripe for rebirth. regards, bp